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ABSTRACT
Background Ostium secundum atrial septal defects
(ASDII) account for approximately 10% of all congenital
heart defects (CHD), and mutations in cardiac
transcription factors, including TBX20, were identified as
an underlying cause for ASDII. However, very little is
known about disease penetrance in families and
functional consequences of inherited TBX20 mutations.
Methods The coding region of TBX20 was directly
sequenced in 170 ASDII patients. Functional
consequences of one novel mutation were investigated
by surface plasmon resonance, CD spectropolarymetry,
fluorescence spectrophotometry, luciferase assay and
chromatin immunoprecipitation.
Results We found a novel mutation in a highly
conserved residue in the T-box DNA binding domain
(I121M) segregating with CHD in a three generation
kindred. Four mutation carriers revealed cardiac
phenotypes in terms of cribriform ASDII, large patent
foramen ovale or cardiac valve defects. Interestingly,
tertiary hydrophobic interactions within the mutant
TBX20 T-box were significantly altered leading to a more
dynamic structure of the protein. Moreover, Tbx20-
I121M resulted in a significantly enhanced transcriptional
activity, which was further increased in the presence of
co-transcription factors GATA4/5 and NKX2-5.
Occupancy of DNA binding sites on target genes was
also increased.
Conclusions We suggest that TBX20-I121M adopts
a more fluid tertiary structure leading to enhanced
interactions with cofactors and more stable
transcriptional complexes on target DNA sequences. Our
data, combined with that of others, suggest that human
ASDII may be related to loss-of-function as well as gain-
of-function TBX20 mutations.
INTRODUCTION
Congenital heart defects (CHD) occur in approxi-
mately 1% of all newborns and are the most
common developmental error in humans. Ostium
secundum atrial septal defects (ASDII) account for
approximately 10% of all CHD. Genetic mutations
have been identified as an underlying cause for
familial recurrence of ASDII in humans.1 Most
disease genes encode cardiac transcription factors
and show autosomal dominant inheritance with
incomplete disease penetrance. Cardiac transcrip-
tion factor genes NKX2-5 and GATA4 are the most
extensively studied for non-syndromic CHD (MIM
600584 and MIM 600576). Thus far, pathogenicity
of CHD related transcription factor mutations is
mainly explained by partial or complete loss of
function resulting in hypomorphic transcriptional
activity.2e4 The most prevalent clinical phenotype
found in probands with transcription factor
mutations is ASDII. Correspondingly, ASDII is the
type of CHD whose familial recurrence is most
extensively documented (MIM 607941).5
T-box genes encode a family of highly conserved
transcription factors that play a crucial role in
organ development.6 Genetic mutations in TBX1
and TBX5 are linked to clinical syndromes also
involving the heart (MIM 188400 and MIM
142900).7 8 TBX20 is an ancient member of the
T-box superfamily highly expressed in embryonic
heart tissues. Genetic ablation of TBX20 causes
failure in cardiac growth and morphogenesis, and
embryonic death at mid-gestation.9 Mutations in
human TBX20 were first reported in two family
pedigrees with a spectrum of ASDII, cardiac valve
defects and cardiomyopathy (MIM 611363).10
Recently, several missense variants in TBX20 have
also been noted in Chinese and American patients
with various CHD, although functional analysis
and family studies to establish pathological status
have not been performed.11 12 To assess the preva-
lence of TBX20 mutations in patients with ASDII,
we sequenced the coding regions of TBX20 in 170
ASDII probands and studied the functional conse-
quences of a novel missense mutation in a highly
conserved T-box region.
PATIENTS AND METHODS
Study population and mutational analysis and
molecular modelling
One hundred and seventy patients with ASDII
attended the Department for Pediatric Cardiology
at the German Heart Institute Berlin and gave
written informed consent. Control subjects
(n¼340) underwent echocardiography to exclude
CHD. In addition 218 ethnically matched control
probands from two clinical centres in Lebanon were
genotyped to exclude TBX20-I121M. Coding region
of TBX20 (NM_020417) was amplified as
described10 and polymerase chain reaction (PCR)
fragments were directly sequenced. The study was
approved by the Institutional Review Board of the
Charité and conforms to the Declaration of
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Helsinki. The homology model of the TBX20 T‑box domain was
produced using the protein structure homology modelling server
SWISS-MODEL13 and based on the structure of the T‑box
domain of human TBX3 (PDB 1h6f).14
Mutagenesis, transfection and transcriptional assays
Full length cDNA expression constructs for wild-type (WT)
mouse TBX20a and c, TBX20-I152M, TBX20-Q195X, NKX2-5,
GATA4 and GATA5 as well as the luciferase reporter vectors
pANF-700-Luc and pGL3-Gja5 have been described previ-
ously.10 15 The I121Mmutation was introduced into pCDNA3.1-
Tbx20a/c by PCR based, site directed mutagenesis and confirmed
by sequencing. COS7 cells were transfected with expression and
reporter vectors using Lipofectamine. CMV-renilla luciferase
reporter vector was used as a control for the transfection efficacy.
Cells were harvested after 24 h and luciferase activity was
measured using the Dual-Luciferase Reporter 1000 assay system
(Promega, Madison, Wisconsin, USA). Transcription data are
listed as average6SEM, representing three independent trans-
fections, each done in triplicate. Statistical analysis was
performed using the Student t test.
Biophysical studies
The T-box domains were expressed as fusion proteins as previ-
ously described.13 Circular dichroism (CD) data were recorded
on a Jasco J‑720 spectropolarimeter equipped with a Neslab
RTE-111 temperature controller as described.11 13 Surface
plasmon resonance kinetic analysis was performed on
a Biacore 2000 SPR instrument. Pairs of oligonucleotides
(CTCTAGTCACACCTAGGTGTGAAATT (T‑site) and
CTCTTATAGGTGTGAAAACCGTG (T/2), with one partner
containing a 59-biotin group, were immobilised on a streptavidin
coated SA sensor chip following the manufacturer ’s protocol.
Binding ofANS (1-anilinonapthalene-8-sulfonic acid)was analysed
with protein at 0.18 mg/ml and ANS at 0.1 mg/ml at pH 7.4. ANS
fluorescence was measured in a Varian CARY Eclipse Fluorescence
spectrophotometer with a temperature controlled cell.
Chromatin immunoprecipitation (ChIP) and quantitative PCR
COS7 cells were grown overnight in 150 mm dishes to 70%
confluency and then co-transfected with the pANF-Luc reporter
vector and expression vectors for TBX20a (WT, I121M, I152M),
Nkx2-5 and Gata4. After 24 h, cells were cross-linked with
formaldehyde, harvested and immunoprecipitations were
performed essentially as described previously.16 Antibodies used
in this procedure include TBX20 (Orbigen, Inc, California, USA),
NKX2-5 (Santa Cruz Biotechnology, Inc, California, USA) and
rabbit IgG. The bound DNA was analysed by semiquantitative
PCR with primers for the Nppa promoter (forward 59-
GAGCGCCCAGGAAGATAACCA-39; reverse 59-AGTGACA-
GAATGGGGAGGGTTCT-39) and the endogenous Hprt
promoter region as a negative control (forward 59-
GGCAGCGTTTCTGAGCCA-39; reverse 59- AAAGCAGT-
GAGGTAAGCCCAAC-39). Real-time PCR was carried out using
the LightCycler 480 DNA SYBR Green I Master mix on
a LightCycler 480 (Roche Applied Science, Mannheim,
Germany) with primers for the Nppa promoter and Gapdh for
normalisation. Fold enrichment relative to WT TBX20 was
calculated using the comparative CT method (DDCT method).
Experiments were repeated at least three times.
RESULTS
One heterozygous C/G transversion at position c.374
(NM_020417) was detected in a 16-year-old male subject of
Lebanese origin with ASDII (figure 1A). The variant results in
a shift from isoleucine to methionine in the TBX20 protein
(I121M) and was not found among 680 control alleles. We also
screened 218 control probands from Lebanon but found no
TBX20-I121M, excluding it as an ethnically restricted poly-
morphism. The affected residue lies in the T-box DNA binding
region and is highly conserved among species (figure 1B). Two in
silico tools (PolyPhen and SIFT)17 18 predicted functional
consequences for the variant. As shown in figure 2 the residue of
Ile121 packs between side chains of Arg127 and Tyr267, which
make important interactions with DNA.14 To investigate disease
segregation in the family pedigree, we characterised relatives of
the proband (figure 1C). The index patient (IV:4) had a cribri-
form ASDII with three distinct perforations in the atrial septum.
The proband’s grandmother (II:2) was reported to suffer from
combined cardiac valve defects and underwent surgical replace-
ment of aortic and mitral valves at age 35. She died at age 55 and
no DNA was available. However, genotyping of proband III:1
and his half-sister (III:2) indicated that II:2 was most likely also
harbouring I121M (figure 1C). Subject III:1 declined clinical
characterisation but consented to genetic analysis. The
proband’s mother (III:2) and sister (IV:2) showed large patent
foramen ovale (PFO) with permanent shunt as seen in trans-
oesophageal echocardiography. Both were positive for the
mutation. Subjects III:3, IV:1 and IV:3 had no atrial shunts or
other echocardiographic abnormalities and did not harbour the
mutation.
To scrutinise alterations in structural stability of I121M we
used CD spectropolarimetry. Figure 3A shows that the I121M
Figure 1 (A) The relevant sequence
electropherogram of TBX20
(NM_020417) exon 2 in the proband.
(B) The affected amino acid (Ile121) lies
in a highly conserved N-terminal region
of the DNA binding T-box region of
TBX20. Affected region of TBX20
homologues and human TBX paralogues
are shown. (C) Family pedigree of
mutation carriers. The proband is
marked with an arrow. All subjects
which were genotyped for TBX20-
I121M are indicated with + (carrier)
or  (non-carrier). Subject II:2 was
presumed positive for TBX20-I121M
(plus symbol in parentheses) as
indicated by the genotypes of progeny
(III:1 and III:2).
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T‑box was folded into a predominantly b‑sheet structure,
virtually identical to that of the WT domain at 208C. Thermal
denaturation of secondary structure in the mutant protein,
monitored as loss of CD ellipticity signal at 215 nm, demon-
strated that the melting temperature of I121M T-box was
approximately 28C lower than that of the WT T-box (figure 3B).
We also probed the tertiary structure of the mutant domain
using binding of ANS, a hydrophobic fluorescent molecule that
displays enhanced fluorescence when surrounded by non-polar
amino acids in proteins. While both WT and TBX20eI121M
T-boxes displayed increased ANS binding at 378C relative to
208C, the I121M mutant showed a significantly greater
fluorescence shift than WT TBX20 at the higher temperature
(figure 3D). The mutation therefore appears to destabilise both
secondary structure, albeit only weakly, and tertiary structural
interactions within the hydrophobic core of the T-box domain,
resulting in a conformation that has a more dynamic tertiary
structure than the WT protein.
To assess structural features further, we measured DNA
binding affinity of the mutant T-box. EMSA on transfected cells
proved to be too insensitive to quantify subtle DNA binding
changes in the context of the full length protein. We therefore
measured the DNA binding kinetics of bacterially expressed
recombinant T‑box protein on the T-half site or T-site DNA
sequences by surface plasmon resonance. The affinity of the
I121M mutant T-box for the binding sites at 208C was not
significantly changed (1.8360.333106 M for I121M vs
1.2460.273106 M for WT) (figure 3C). Attempts to measure
the DNA binding affinity at 378C failed because prolonged
incubation of the I121M T-box at this temperature led to
aggregation and irreversible binding to the sensor chip.
We next tested transcriptional activity of mutant and WT
TBX20 using luciferase assays. The long isoform of WT TBX20
(TBX20a) has weak intrinsic transcriptional activity, likely
because of the dominant effects of its C-terminal repression
domain.15However, strong synergistic transcriptional potential in
Figure 2 (A) The homology model of
TBX20, based on the structure of
human TBX3, suggests that the side
chain of Ile121 packs between the side
chains of Arg127 and Tyr267 and
adjacent to Thr269. (B) In TBX3, the
residues equivalent to Arg127 and
Tyr267 (Arg130 and Tyr264) make
important interactions with the DNA,
making it possible that changes at
residue 121 might affect the binding of
the T-box to DNA.
Figure 3 Biophysical characterisation
of the I121M variant T‑box. (A) Far UV
CD spectra of WT (solid line) and I121M
variant (dashed line) TBX20 T‑box
domains indicate similar folded, b‑sheet
rich secondary structures. (B)
Proportion of secondary structure
folded as protein is heated. The I121M
variant (dashed line) domain displays
a w28C reduction in Tm compared to
WT (solid line), as measured by loss of
CD signal at 215 nm. (C) Binding curves
for I121M (dashed line) and WT (solid
line) from representative surface
plasmon resonance kinetic experiment.
The mutation does not significantly
affect the affinity of the domain for the
T‑site, as evidenced by very similar
rates for binding and dissociation from
the DNA displayed by both domains. (D)
ANS fluorescence measured for I121M
at 208C and 378C (solid and open
triangles, respectively) and WT TBX20
T‑box at 20 and 378C (solid and open
squares, respectively). Both domains
show increased ANS binding at 378C,
a sign that tertiary contacts are
relatively weak but the variant binds
more ANS than the WT domain,
indicating that the mutation destabilises
the hydrophobic core further.
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TBX20a is revealed when it is expressed with interacting tran-
scription factors NKX2-5 and GATA4 (Nppa promoter10) or
NKX2-5 andGATA4 (Gja5promoter15). The shortTBX20 isoform
(TBX20c) lacks theC-terminal repression and activation domains,
and shows a higher baseline activity when overexpressed.
TBX20c-I121M alone induced significantly higher activation of
both theNppa andGja5 enhancers compared toWTTBX20c (23%
and 99%, respectively, p¼0.01/0.04; figure 4A,C). A similar result
was seen when the I121M mutation was introduced into the
human TBX20 cDNA (data not shown). The increased activity of
the mutant was even more apparent in the presence of NKX2-5
and GATA4/5 for both target genes (Nppa: 162%, p¼0.01; Gja5:
127%, p¼0.004; figure 4B,D). In contrast, previously identified
TBX20 nonsense mutation Q195X resulted in reduced transcrip-
tional activity, while the mis-sense mutation I152M, which
showed reduced DNA binding on-rate, also displayed a gain-of-
function transcriptional activity in some assays.10
To obtain further insight into these gain-of-function proper-
ties of I121M, we tested the occupancy of TBX20 WT and
mutant proteins, and NKX2-5, on respective DNA binding sites
within the Nppa enhancer in transfected COS7 cells by ChIP.
Immunoprecipitation of cross-linked DNA/protein complexes
with a TBX20 or NKX2-5 antibody, followed by semi-
quantitative (figure 5A) and real-time PCR (figure 5B), revealed
significantly enhanced occupancy of the I121M, on the Nppa
promoter. In contrast the previously identified ASDII mutation
I152M, which showed decreased DNA binding,10 also displayed
decreased occupancy. NKX2-5 revealed enhanced occupancy in
the presence of TBX20-I121M and decreased occupancy with
the TBX20-I152M mutation.
DISCUSSION
We describe a novel mutation in TBX20 associated with CHD in
a kindred spanning three generations. The cardiac phenotypes of
TBX20-I121M carriers are of particular interest: the proband
harbouring I121M had a multiperforated atrial septumda crib-
riform ASDII. During embryonic development, the septum
primum grows from the primordial atrial roof towards the
Figure 4 Transcriptional activity of
WT and mutated TBX20 (I121M) and of
the previously published TBX20
mutations I152M and Q195X. (A) Fold
activation of a luciferase reporter
construct carrying the proximal
promoter elements of the Nppa gene
after cotransfection of COS7 cells with
expression constructs for WT and
mutant TBX20 (short isoform). (B)
Activation of the Nppa promoter in the
presence of mutant and WT TBX20a
(full length isoform), NKX2-5 and
GATA4. (C, D) Fold activation of
a luciferase reporter carrying proximal
promoter elements of the Gja5 gene.
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endocardial cushion. Simultaneously, small perforations develop
in the upper part of the septum primum as a result of cell death,
which coalesce with each other to form the foramen secundum.
Cribriform ASDII are the result of an incomplete mergence of
these perforations as well as an insufficient growth of the
septum secundum. Interestingly, we and others have previously
identified cribriform ASDII as a cardiac phenotype in patients
with mutations in NKX2-5 and GATA4.19 20 Thus, one may
hypothesise that cribriform ASDII is overrepresented among
patients with genetic ASDII and can result from perturbations
to multiple individual transcription factors acting within an
interactive regulatory network controlling atrial septation. The
cardiac phenotypes of the proband’s relatives were convergent
with clinical features in patients harbouring the presumed
TBX20 loss-of-function mutation Q195X,10 confirming a crucial
role for normal levels of TBX20 activity in human atrial septa-
tion and valvulogenesis. Two I121M carriers (III:2 and IV:2) had
so far undiagnosed atypically large PFOs accompanied by
a permanent left to right shunt. These findings are also in
accordance with patients harbouring different mutations in
TBX20.10 11 PFOs derive from incomplete adhesion of the
septum primum to the septum secundum after birth, leaving
a functional communication between both atria via oblique, slit
shaped tunnels. PFOs have a prevalence of approximately 30% in
the general population. However, large PFOs with a defect of
10 mm or more as noted in the two TBX20-I121M carriers are
found in only 1.3% of the population.21 Human family studies
strongly indicate familial clustering of PFO and ASD, especially
those with larger defects and atrial shunts.22 23 However, very
little is known about genetic defects related to human PFO.
Studies with inbred mice carrying heterozygous Nkx2-5 muta-
tions reveal defects in atrial septal morphogenesis resulting in
ASDII as well as PFO, the latter depending on atrial morpho-
logical characteristics including length of the septum primum.24
Quantitative trait loci analyses in different mouse strains
strongly support the notion of an anatomic continuum between
secundum ASD and PFO.25 Notably, TBX20 overlaps with one
such suggestive QTL (unpublished data Richard P Harvey, 2006).
An interesting finding of the present study was the mutation
related gain-of-function. In contrast to most previously charac-
terised CHD associated mutations, Tbx20-I121M showed
significantly enhanced transcriptional activity of two target
genes. Enhanced activity was even more pronounced when
TBX20-I121M was co-expressed with NKX2-5 and GATA4/5.
Importantly, I121M also showed enhanced occupancy of Nppa
promoter DNA in transfected cells in the ChIP. These properties
were observed in the absence of effects on DNA binding (albeit
measured at 208C) and the secondary structure of the mutant T-
box was only slightly less thermally stable than that of the WT.
However, tertiary packing in the hydrophobic core was signifi-
cantly weakened by the mutation. The tertiary structure of the
WT TBX20 T-box is far less thermally stable than that of
parologous factors TBX5 and TBX2. Indeed, TBX20 therefore
has unique biophysical characteristics compared to other cardiac
T-box proteins in that it populates a molten globule state at
378C.13 The I121M mutant T-box displayed an even more
dynamic tertiary structure than the WT T-box. While enhanced
occupancy of target promoters could in principal be related to
enhanced DNA binding, this was not observed and there are
other possibilities, such as an enhanced rate of scanning of DNA
or cofactors for interaction, or enhanced structural stability
when bound to cofactors. The increased occupancy of NKX2-5
supports the idea of a more stable transcriptional complex and
our data suggest that complex formation and/or stability is
driven to a significant degree by transcription factor interactions,
in this case between TBX20 and NKX2-5. Nevertheless, caution
should be exercised in extrapolating the in vitro data to the in
vivo situation. Though a significant gain-of-function was
observed in multiple transcriptional assays, the protein might be
less stable in vivo converging with a loss-of-function phenotype.
In vitro studies with CHD associated mutations in NKX2-5
and GATA4 revealed in most cases an impaired transactivation
with either preserved or decreased DNA binding affinity.2e4 It is
therefore generally appreciated that haploinsufficiency of tran-
scription is a common genetic root of CHD.1 However, Postma
and colleagues characterised a novel TBX5 missense mutation
found in a family with atypical Holt Oram syndrome displaying
enhanced transcription of several target genes associated with an
increased DNA binding affinity.26 Moreover, TBX20 was shown
to be significantly upregulated in ventricular tissue from CHD
Figure 5 Immunoprecipitation assay
with transiently transfected COS7 cells
using an antibody against TBX20 and
NKX2-5, followed by semiquantitative
and real-time PCR reveals an enhanced
occupancy of the Nppa promoter. Fold
enrichment relative to WT Tbx20 was
calculated using the comparative CT
method. HPRT unrelated negative
control; Rabbit IgG: negative control
antibody. Lower panel: schematic
diagram of the proximal Nppa promoter
indicating the positions of T-box, GATA,
and Nkx2 factor binding sites. The
positions of the primers used for the
ChIP analysis are indicated as
arrowheads.
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patients which may cause an increased activity in cardiomyo-
cytes.16 It is important to note, however, that the degree of
relationship between functional consequences of gene mutations
and specific anatomic findings remains highly speculative and
additional genetic variants and environmental factors can
influence clinical features of mutation carriers.
In conclusion, we have identified one novel missense variant
in TBX20 associated with congenital atrial septal and cardiac
valve defects resulting in unique biophysical properties
compared to previously studied TBX20 mutations related to
CHD. Notably, the mutation exhibited significantly increased
transcriptional activity in vitro, as well as increased synergy
with its cardiac co-transcription factors NKX2-5 and GATA4/5,
and increased occupancy on the DNA of two target genes.
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